In vitro effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical Mycobacterium abscessus isolates.
Izumi YamataniAkio AonoKeiji FujiwaraTakahiro AsamiKeisuke KamadaYuta MorishigeYuriko IgarashiKinuyo ChikamatsuYoshiro MuraseHiroyuki YamadaAkiko TakakiKosaku KomiyaSatoshi MitaraiPublished in: Microbiology spectrum (2024)
pulmonary disease.